tbuckley/cabot-search huggingface dataset:
Prognostic factors in ovarian cancer patients with brain metastases: Results of a German multicenter study
Authors: K. El Khalfaoui, G. Oskay-Ozcelik, R. Richter, K. Pietzner, P. Harter, K. Münstedt, S. Mahner, A. Hasenburg, P. Wimberger, J. Sehouli
Journal: Journal of Clinical Oncology (2009)

e16527 Background: Ovarian cancer is one of the leading causes of mortality in women with gynaecological malignancies. Brain metastases from ovarian cancer are rare. Up to this point there are only few data about prognostic factors for this patient collective. Methods: Within a period between 1981 and 2008 we analyzed 4,277 women with histologically confirmed ovarian cancer from six different German hospitals. Overall 72 women with brain metastases and two cases of meningosis carcinomatosa were identified, these resulting in an incidence of 1.73%. Results: The median age at the diagnosis of central nervous system (CNS) metastases was 58 years (range, 33–83). The median interval between the time of the first diagnosis of ovarian cancer and the occurrence of CNS metastases was 28.8 months (range, 3.6 -133.1). The median overall survival time after diagnosis of CNS metastases was 6.1 months (range, 0.2 -41.5). Multiple brain metastases were observed in 58 women (78.4%). Headache (36.5%), vomiting and nausea (17.1%) were the most frequent clinical symptoms. According the multivariate analysis following clinical parameter reached statistical significance: multiple lesions (hazard ratio (HR): 4.1, 95% confidence intervaI (CI): 1.9 to 8.9), grading I und II (HR: 2.8, 95% CI: 1.6 to 5.0) were associated with a negative impact on overall survival. Platinum sensitivity (HR: 0.28, 95% CI: 0.15 to 0.52) and the application of multimodal therapy strategies (surgery, radiotherapy and chemotherapy) (HR: 0.51, 95% CI: 0.28 to 0.92) and the good performance (HR: 0.52; 95% CI: 0.25 to 1.08) showed a positive impact on overall survival. Tumour histology, ascites and age at the CNS diagnosis were not significant for the survival. Conclusions: Next to the presence of multiple brain lesions and the performance status, the sensitivity to platinum based chemotherapy has an important positive impact on overall survival. This should be considered in the conduction of multimodal therapy strategies for brain metastases from ovarian cancer. No significant financial relationships to disclose.
LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia
Authors: Goichi Tatsumi, Masahiro Kawahara, Ryusuke Yamamoto, Masakatsu Hishizawa, Katsuyuki Kito, Takayoshi Suzuki, Akifumi Takaori-Kondo, Akira Andoh
Journal: Leukemia (2019)
SCIDOT-48. EVALUATING THE THERAPEUTIC EFFICACY AND CONVECTION ENHANCED DELIVERY (CED) TOXICITY ANALYSIS OF CDK4/6 INHIBITOR PALBOCICLIB FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
Authors: Dennis Lee, Uday Maachani, Oluwaseyi Adeuyan, Sergio Guadix, Mark Souweidane
Journal: Neuro-Oncology (2019)

Abstract DIPG is a devastating, aggressive brain tumor of childhood. No chemotherapeutic agent has so far shown significant clinical efficacy and focal radiation therapy provides only temporary relief. Recent studies on the genomic aberrations of pediatric gliomas have shown that a subset of these tumors harbor focal gains in proteins of the cyclin-dependent kinase (CDK) 4/6 cell cycle pathway. H3.3K27M mutation, associated with &gt;80% of DIPGs, has also been associated with epigenetic silencing of p16 tumor suppressor, an important effector in regulating CDK4/6 pathway. In this study, we characterized and confirmed through immunoblot analysis that proteins involved in CDK 4/6 pathway, including Rb1, are intact in multiple patient derived DIPG (SU-DIPG-IV, SU-DIPG-XIII, SU-DIPG-XVIII, SF8628) and wild type (SF9428) cell lines. Expression of p16 was decreased or undetectable in DIPG cells compared to normal astrocytes. In addition, pharmacologic inhibition of CDK4/6 with palbociclib showed dose dependent reduction in DIPG cell proliferation with IC50 ranging from 5.42uM to 21.35uM between different cell lines. However, major problems of palbociclib are that it does not readily cross the blood-brain-barrier (BBB) and has major systematic toxicities, such as myelosuppression, which limits oral dosing. One solution to overcome the BBB is convection enhanced delivery (CED) which is a form of local delivery that bypasses the BBB by placement of small diameter catheters directly into the brain tumor. With this approach, high regional drug concentration can be achieved with negligible systemic toxicity. In this study, we also observed no significant short- or long-term neurotoxicity of palbociclib delivered via CED in a mouse model. We hypothesize that the CDK4/6 cell cycle pathway has an important role in DIPG tumorigenesis and progression and that existing therapies targeting these pathways, which are already in clinical use for other cancers, can be rapidly repurposed for the treatment of DIPG through CED.
Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies
Authors: Jie Ding, Kendra L Davis-Plourde, Sanaz Sedaghat, Phillip J Tully, Wanmei Wang, Caroline Phillips, Matthew P Pase, Jayandra J Himali, B Gwen Windham, Michael Griswold, Rebecca Gottesman, Thomas H Mosley, Lon White, Vilmundur Guðnason, Stéphanie Debette, Alexa S Beiser, Sudha Seshadri, M Arfan Ikram, Osorio Meirelles, Christophe Tzourio, Lenore J Launer
Journal: The Lancet Neurology (2019)
Preclinical Assessment of Non-Virally Engineered CD33.CAR Cytokine-Induced Killer (CIK) Cells in Chemoresistant AML Patient-Derived Xenografts
Authors: Maria Caterina Rotiroti, Chiara Buracchi, Silvia Arcangeli, Chiara F Magnani, Claudia Cappuzzello, Zsuzsanna Izsvak, Stefania Galimberti, Maria Grazia Valsecchi, Giuseppe Dastoli, Marta Serafini, Ettore Biagi, Andrea Biondi, Sarah Tettamanti
Journal: Blood (2019)
Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia
Authors: Amanda Przespolewski, Craig W. Freyer, Wenyan Ji, Tara L. Cronin, Swapna Thota, Elizabeth A. Griffiths, James E. Thompson, Amro Elshoury, Jeffrey Baron, Mark Walsh, Eunice S. Wang
Journal: Blood (2019)
PATH-55. MUTATIONS OF H3.3 AND H3.1 IN A LARGE COHORT OF GLIOMAS
Authors: Ashley Sumrall, Sandeep Mittal, Surasak Phuphanich, Amy Heimberger, Jenny Eschbacher, Michael Korn, Zoran Gatalica, Manjari Pandey, Joanne Xiu
Journal: Neuro-Oncology (2019)

Abstract Mutations in the histone genes H3.3 and H3.1 are driver events in pediatric and adult gliomas and carry diagnostic and prognostic importance for tumors originating from midline structures. Patients with tumors affected by these mutations are difficult to treat. We surveyed a large cohort of gliomas for H3-mutations, including H3K27m. Consecutive gliomas submitted for tumor profiling at Caris Life Sciences from 2015- 2019 were analyzed. NextGen sequencing was done on 592 genes; MGMT promoter methylation was tested by pyrosequencing; and EGFRvIII and gene fusions were tested by RNA-sequencing. Of nearly 1800 tumors analyzed, 41 harbored H3F3A alterations, including 33 with the K27M mutation (4 arose from the spinal cord, 1 from cerebellum, 1 from brain stem, 4 from thalamus, and 23 from brain, NOS). Eight G34R mutations were identified. A HIST1H3B-K27M was detected in a tumor from the brain stem. H3 mutations were more prevalent in pediatric tumors, and all H3 mutations seen in pediatric tumors were from grade IV tumors. Among the H3-mutated adult tumors, histology differed. There were 2 grade II tumors, 1 low grade glioma, 1 anaplastic ganglioglioma, and 2 anaplastic astrocytomas. In the investigated cohort, H3-mutations were mutually exclusive of IDH1/2 mutations and EGFR alterations. Significantly higher mutation rates were seen in H3-mutated tumors for TP53, ATRX, NF1, PDGFRA, FGFR1, FBXW7, BLM, and TSC2 compared with H3-WT. The H3-WT tumors were more enriched for MGMT-methylation and PTEN mutation. In H3-mutated tumors that were MGMT-methylated, most H3-mutations seen were G34R while K27M was largely exclusive. There was a heterogeneous distribution of H3 mutations, and the co-occurring molecular alterations seen in H3-mutated tumors further support the hypothesis that these tumors are a distinct molecular entity. By better characterizing these associations, we can develop insight into novel treatment strategies for a class of tumors with historically dismal prognosis.
CMV-Specific T Cells Restricted By Shared and Donor, but Not By Host HLA Molecules Reconstitute in the First 180 Days after Allogeneic HSCT and Protect from CMV Reactivation: Results of a Prospective Observational Study
Authors: Maddalena Noviello, Elena Tassi, Pantaleo De Simone, Francesca Serio, Maria Teresa Lupo Stanghellini, Giacomo Oliveira, Sara Racca, Roee Dvir, Lorenzo Lazzari, Daniela Clerici, Fabio Giglio, Francesca Lorentino, Consuelo Corti, Massimo Bernardi, Liselotte Brix, Fabio Ciceri, Jacopo Peccatori, Raffaella Greco, Chiara Bonini
Journal: Blood (2019)
Comparing Costs Associated to Letermovir Prophylaxis Vs Ganciclovir Pre-Emptive Therapy in HCMV-Seropositive Patients Who Undergone to Hemopoietic Stem Cells Transplantation
Authors: Oscar Borsani, Daniele Lilleri, Elisa Gabanti, Gabriela Cassinelli, Anna Amelia Colombo, Daniela Caldera, Emilio Paolo Alessandrino, Paolo Bernasconi
Journal: Blood (2019)
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
Authors: Marieke J. Krimphove, Karl H. Tully, David F. Friedlander, Maya Marchese, Praful Ravi, Stuart R. Lipsitz, Kerry L. Kilbridge, Adam S. Kibel, Luis A. Kluth, Patrick A. Ott, Toni K. Choueiri, Quoc-Dien Trinh
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> The introduction of immune checkpoint inhibitors has led to a survival benefit in patients with advanced melanoma; however data on the adoption of immunotherapy in the community are scarce. <h3>Methods</h3> Using the National Cancer Database, we identified 4725 patients aged ≥20 diagnosed with metastatic melanoma in the United States between 2011 and 2015. Multinomial regression was used to identify factors associated with the receipt of treatment at a low vs. high immunotherapy prescribing hospital, defined as the bottom and top quintile of hospitals according to their proportion of treating metastatic melanoma patients with immunotherapy. <h3>Results</h3> We identified 246 unique hospitals treating patients with metastatic melanoma. Between 2011 and 2015, the proportion of hospitals treating at least 20% of melanoma patients with immunotherapy within 90 days of diagnosis increased from 14.5 to 37.7%. The mean proportion of patients receiving immunotherapy was 7.8% (95% Confidence Interval [CI] 7.47–8.08) and 50.9% (95%-CI 47.6–54.3) in low and high prescribing hospitals, respectively. Predictors of receiving care in a low prescribing hospital included underinsurance (no insurance: relative risk ratio [RRR] 2.44, 95%-CI 1.28–4.67, <i>p</i> = 0.007; Medicaid: RRR 2.10, 95%-CI 1.12–3.92, <i>p</i> = 0.020), care in urban areas (RRR 2.58, 95%-CI 1.34–4.96, <i>p</i> = 0.005) and care at non-academic facilities (RRR 5.18, 95%CI 1.69–15.88, <i>p</i> = 0.004). <h3>Conclusion</h3> While the use of immunotherapy for metastatic melanoma has increased over time, adoption varies widely across hospitals. Underinsured patients were more likely to receive treatment at low immunotherapy prescribing hospitals. The variation suggests inequity in access to these potentially life-saving drugs.
Immune Biomarkers of Early-Life Adversity and Exposure to Stress and Violence—Searching Outside the Streetlight
Authors: Nicole R. Bush, Kirstin Aschbacher
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade
Authors: Shadi Swaidani, Joanna Roopkumar, Young Jun-Shim, Cathy Charles, Slato Paul, Suman Kundu, Pauline Funchain, Patricia Rayman, Paul G. Pavicic, C. Marcela Diaz-Montero, Alok A Khorana, Keith R McCrae
Journal: Blood (2019)
Whole Genome Sequences of Epstein-Barr Viruses Associated with Burkitt Lymphoma Tissues
Authors: Haiyan Lei, Tianwei Li, Shien Tsai, Robert J Biggar, Francis Nkrumah, Janet Neequayee, Marina Gutierrez, Sidnei Epelman, Shyh-Ching Lo, Sam M Mbulaiteye, Kishor Bhatia
Journal: Blood (2014)
RARE-04. TARGETED TREATMENT OF PAPILLARY CRANIOPHARYNGIOMAS HARBORING BRAFV600E MUTATIONS
Authors: Tareq Juratli, Pamela Jones, Nancy Wang, Megha Subramanian, Simon Aylwin, Yazmin Odia, Elham Rostami, Olafur Gudjonsson, Brian Shaw, Daniel Cahill, Joon Uhm, Evanthia Galanis, Fred Barker, Sandro Santagata, Priscilla Brastianos
Journal: Neuro-Oncology (2019)

Abstract Craniopharyngiomas are surgically challenging brain tumors. Postoperatively, quality of life is often significantly impaired due to neurological and endocrinological complications. Currently, FDA approved systemic treatments are not available for patients in whom craniopharyngiomas recur after surgery and radiation. Papillary craniopharyngiomas are characterized by the presence of BRAFV600E mutations. To date, five case reports have been published on the treatment of BRAFV600E mutant papillary craniopharyngiomas with BRAF and/or MEK inhibitors. In this presentation, authors from all five previously published reports share their collective experience and provide updated follow-up on their patients, thus generating an overview of all currently available information on targeted therapy in patients with BRAFV600E mutant papillary craniopharyngiomas. We have also included information on an additional patient with a papillary craniopharyngioma recently treated with BRAF and MEK inhibitors after tumor biopsy alone, in the absence of recurrence, highlighting the potential for a neo-adjuvant therapeutic approach. All six cases in our series showed dramatic responses to targeted treatment with BRAF (and MEK) inhibitors. Collectively, our cases are highly promising and informative for patient treatment, although uncertainty remains with regards to the optimal timing, the specific agents (single agent or dual therapy) to be used and the duration of treatment. The ongoing multicenter phase II Alliance A071601 trial (NCT03224767) of vemurafenib and cobimetinib for patients with biopsy-proven residual or recurrent papillary craniopharyngiomas should provide additional information to help guide patient management.
U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA Complex
Authors: Giulia Biancon, Poorval Joshi, Torben Hunck, Yimeng Gao, Valentina Botti, Ashley Qin, Mukhtar Sadykov, Xiaman Wang, Gabriella Viero, Nils Neuenkirchen, Ashley Taylor, Jane Huang, Anastasia Ardasheva, Xiaoying Fu, Haifan Lin, Manoj M Pillai, Clara L Kielkopf, Karla M Neugebauer, Toma Tebaldi, Stephanie Halene
Journal: Blood (2019)
Medical cannabis registry launched to build up evidence base
Authors: Jacqui Wise
Journal: BMJ (2019)

A national medical cannabis registry has been launched for the UK to build a body of evidence to support NHS prescribing.1

A year after cannabis medicines were made legal in the UK, only a handful of patients have been able to access prescriptions on the NHS, according to campaigners.2 Doctors have been reluctant to prescribe cannabis based products because of a lack of evidence about safety and effectiveness. As a result, patients feel forced to get medical cannabis products through prescriptions given by private clinics or the illicit market.

Project Twenty21, set up by the independent scientific body Drug Science, aims to enrol up to 20 000 patients by the end of 2021. Patients …
Novel Immune Checkpoint Deficiency and Susceptibility to EBV-Associated Lymphoma
Authors: Ido Somekh, Thomas Magg, Alejandro Gallón Duque, Tali Stauber, Atar Lev, Ekrem Unal, Amos J. Simon, Meino Rohlfs, Raffaele Conca, Megumi Tatematsu, Fabian Hauck, Raz Somech, Christoph Klein
Journal: Blood (2019)
Role of Low Albumin Levels in Pediatric Patients with Central Venous Catheters at Risk for Thrombosis
Authors: Neha Bhasin, Denise Roe, Janna M. Journeycake, Chelsea Large, Kathylynn Saboda, Beth Boulden Warren, Marilyn J Manco-Johnson, David T. Harris, Michael Badowski, Lynn Gerald, Vivian Moreno, Steven R. Lentz
Journal: Blood (2019)
Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients
Authors: Claire L. Ihle, Meredith D. Provera, Desiree M. Straign, E. Erin Smith, Susan M. Edgerton, Adrie Van Bokhoven, M. Scott Lucia, Philip Owens
Journal: Journal for ImmunoTherapy of Cancer (2019)

The most common metastatic lesions of prostate cancer are in bone and can be classified into three distinct pathology subtypes: lytic, blastic, and an indeterminate mixture of both. We investigated a cohort of decalcified formalin-fixed and paraffin-embedded (FFPE) patient specimens from the bone that contained metastatic prostate cancer with lytic or blastic features. These tissue sections were utilized for immunohistochemistry (IHC) staining, isolation of RNA for gene expression, and Digital Spatial Profiling (DSP) of changes in both the tumor and microenvironment. A diverse set of unique immune cell populations and signaling pathways to both lytic and blastic types of prostate cancer metastases were present. In blastic lesions immune cells were enriched for pSTAT3 and components of the JAK-STAT pathway. In lytic-type lesions, immune cells were enriched for pAKT activity and components of the PI3K-AKT pathway. Enrichment for immune checkpoints including PD-L1, B7-H4, OX40L, and IDO-1 were identified in blastic prostate cancer, providing new therapeutic targets for patients with bone metastases. Biopsies could guide selection of patients into appropriate therapeutic interventions based on protein levels and RNA expression of desired targets in metastatic disease. Molecular pathology has been an excellent complement to the diagnosis, treatment, and management of primary tumors and could be successfully extended to patients with metastatic lesions.
Deviation from Guidelines in Use of Eltrombopag and Romiplostim in Clinical Practice for Children with Primary Immune Thrombocytopenia; Multi-Center Egyptian Experience
Authors: Mohsen Saleh Elalfy, Tamer Hassan, Khalid Elsayh, Mohamed Maebid, Hoda Hassab, Rasha Elashry, Mona El ghamrawy, Mahmoud Elhawy, Marwa Zakaria, Mohamed Elshanshory
Journal: Blood (2019)
Discovery &amp; Characterization of Therapeutically Targetable Ntrk Point Mutations in Leukemia
Authors: Sunil K Joshi, William Bisson, Kristin Qian, Ariane Huang, Kevin Watanabe-Smith, Jeffrey W. Tyner, Monika Ashok Davare, Shannon K. McWeeney, Cristina E. Tognon, Brian J. Druker
Journal: Blood (2019)
Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches
Authors: Sophia Adamia, Daisuke Ogiya, Ivane Abiatari, Sigitas J Verselis, Michael P. Chu, David M. Dorfman, Linda M. Pilarski, Teru Hideshima, Kenneth C. Anderson
Journal: Blood (2019)
First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma
Authors: Edward A. Stadtmauer, Adam D. Cohen, Kristy Weber, Simon F Lacey, Vanessa E. Gonzalez, J. Joseph Melenhorst, Joseph A Fraietta, Gabriela Plesa, Joanne Shea, Tina Matlawski, Amanda Cervini, Patricia Mangan, Avery Gaymon, Stephanie Desjardins, Eric Lancaster, January Salas-Mckee, Megan M. Suhoski, Andrew Fesnak, Matthew O'Rourke, Anne Lamontagne, Don L. Siegel, Regina M Young, Anne Chew, Christopher L Nobles, Frederic D. Bushman, Howard Y. Chang, Ansuman T. Satpathy, Yangbing Zhao, Wei-Ting Hwang, Elizabeth O. Hexner, Carl H June
Journal: Blood (2019)
Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs
Authors: Candida Vitale, Chiara Salvetti, Valentina Griggio, Maria Cristina Scamuffa, Giulia Zamprogna, Andrea Visentin, Ramona Cassin, Luca Laurenti, Roberta Murru, Paolo Rivela, Monia Marchetti, Massimo Gentile, Elsa Pennese, Gianluigi Reda, Livio Trentin, Alessandra Tedeschi, Francesca Romana Mauro, Robin Foà, Mario Boccadoro, Marta Coscia
Journal: Blood (2019)
TMIC-49. ABROGATING CD70 EXPRESSION IN GBM RESULTS IN A REDUCED IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT
Authors: Haipeng Tao, Linchun Jin, Hector Mendez-Gomez, Yu Long, Meng Na, Alicia Hou, Aida Karachi, Zhiguo Lin, Loic Deleyrolle, Elias Sayour, Duane Mitchell, Jianping Huang
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND We found that CD70, as an immune modulator, in GBM plays a critical role in immunosuppression and tumor progression. Although CD70+ tumors recruit more CD3+ T cells than CD70— tumors do in patients with GBM, CD70 on GBM is also found to be involved in promoting CD8+ T cell death. The experiments by overexpressing or silencing CD70 in a primary tumor demonstrate that it can alter cell growth, survival, migration, and morphology of GBM cells. CD70 is negatively correlated with survival in patients with gliomas. These results suggest that CD70 is involved in immunosuppression in GBM. OBJECTIVE To determine if abrogating CD70 in tumor using CD70CAR-T cells could reverse the immunosuppressive microenvironment and enhance overall endogenous tumor immunity against both CD70+ and CD70— tumors, which might help to overcome a key obstacle— tumor-heterogeneity using single-targeted CAR-T cell therapy. METHODS CD70 was overexpressed (~75% positivity) in KR158 GBM line. Murine CD70CAR T cells were used to eliminate CD70+ tumors in an immunocompetent orthotopic tumor mouse model. Tumor-bearing mice were administered the CD70CAR T and vector-tranduced T cells, followed by IVIS imaging for tumor growth. The presentation and phenotype of CAR T cells and endogenous immune cell populations in tumors and spleens were measured. RESULTS Five weeks post treatment, CD4+ T cells were found to be the dominant T cell population in tumors for both CAR-T and endogenous T cells. While the CAR-T cells shrank the tumors, fewer PD-1 expressing endogenous T cells, as well as granulocytic MDSC, but not monocytic MDSC were observed in the tumor (not in spleen) for the CAR-T group, compared to the vector group. No significant changes were seen for NK cells and Tregs between the groups. CONCLUSION This study suggests that eliminating CD70+ tumor cells may reverse the immunosuppressive landscape of the tumor microenvironment.